Biological Activity
LMT-28 (LMT28) is a specific blocker of IL-6 signaling via inhibits IL-6Rβ (gp130) with IC50 of 5.9 uM (IL-6–induced luciferase activity), selectively inhibits IL-6–induced phosphorylation of STAT3, JAK2, and gp130; does not affect LIF-induced STAT3 activation and not inhibit IL-11 stimulation on HepG2 cells; binds directly and specifically to gp130, and thereby inhibits the interaction of gp130 with the IL-6/IL-6Rα complex; inhibits IL-6–induced proliferation of the human erythroleukemic cell line TF-1 with IC50 of 7.5 uM; inhibits IL-6–induced TNF-α production, ameliorates the progression of pancreatitis in mice.
In Vitro
No in vitro data are provided in the current product source. Contact us for further information.
In Vivo
No in vivo data are provided in the current product source. Contact us for further information.
References & source
References 1. Hong SS, et al. J Immunol. 2015 Jul 1;195(1):237-45. 2. Armstead WM, et al. Transl Stroke Res. 2018 Feb 23. doi: 10.1007/s12975-018-0617-z. View Related Products by Target Interleukin Receptor
Published experimental findings depend on the model and assay conditions. They do not guarantee equivalent performance in every application. For laboratory research use only.











